BMT Drugs Flashcards
Abatacept (orencia)
Selective T-cell costimulation blocker- binds CD80 and CD86
-10 mg/kg IV day before transplant, then on days 5, 14, and 28
-to prevent GVHD in combo with CNI and MTX in mismatched unrelated donor
Antithymocyte globulin equine (Atgam)
Immunosuppressant
-can be given for steroid refractory acute GVHD tx
-can do test ID dose to assess for anaphylaxis
Antithymocyte globulin rabbit (Thymoglobulin)
Immunosuppressant
-can be given as part of conditioning regimen for GVHD prevention
Belumosudil (Rezurock)
Rock2 inhibitor
-steroid refractory chronic GVHD after 2 prior lines of therapy
-DDI with PPIs- increase dose to BID
-skin, GI, joint, **eyes, oral, liver, lungs **
Busulfan (Busulfex, Myleran)
Alkylating agent
-daily or Q6h
-used in myeloablative and reduced intensity regimens
-IV most common but can use PO (inter patient variability with PO)
-can use TDM
-seizure ppx with keppra
-DLTs: pulmonary fibrosis, hepatotoxicity, mucositis
-caution in pulmonary dysfunction
-sinusoidal obstruction syndrome -ursodiol ppx
-pharmacokinetic monitoring
-Q6h IV: AUC goal 3.9-6.2
-daily iv: AUC goal 14.8-24.6
-DDI- azoles, APAP, metronidazole (all increase busulfan)- avoid APAP/met 72h before and after, also phenytoin
-hepatic metabolism via enzymatic conjugation with glutothione
Carmustine (BiCNU)
Alkylating agent
-in BEAM regimen (often used in autologous for lymphoma)
-can cause infusion rxn, HA, perioral paradthesia, flushing d/t etoh in formulation- doses >150 mg/m2 (give APAP, HM, or BZD to mitigate)
-pulmonary toxicity >450 mg/m2- give steroids pred 1mg/kg/d
-renal elimination
-avoid drugs that can cause disulfiram like rxn d/t etoh content
Cyclophosphamide (Cytoxan)
Alkylating agent
-used in mx drug regimens
-hemorrhagic cystitis if high doses
-cardio toxicity >150 mg/kg (at ~10days)- monitor w/ ECG
-also used in GVHD ppx
-hepatotoxicity
DI: Give before busulfan and thiotepa
Busulfan and phenytoin increase cyclo metabolism to toxic metabolites
Cyclosporine (Gengraf, Neoral)
Calcineurin inhibitor
-commonly used for pts with aplastic anemia
-used to prevent and tx GVHD
-renal toxicity, hypomagnesemia, hyperkalemia, and HTN
-rarely causes PRES (posterior reversible encephalopathic syndrome)
-many DDIs including letermovir and 3A4 substrates
-200-300 ng/mL
-IV:PO 1:4 (sandimmune), 1:2-3 (modified)
Hirtuism (unlike tacrolimus)
Cytarabine
Pyramidine analog
-used in BEAM conditioning regimen
-DLT: neurotoxicity (but most transplant regimens are no high dose- they are usually <1g/m2/dose)
Etoposide (toposar)
Topo-II inhibitor
-commonly used in mx drug regimens
-if undiluted it can cause hypotension and precipitation so give with high volume of fluid
-metabolic acidosis- large amount of etoh
-DLT: mucositis
-3A4 substrate- interactions!
-metabolized in liver then renally excreted, 1/3 renally excreted unchanged
-renal elimination increases with hepatic impairment
Fludarabine (Fludara)
Purine analog
-common drug used in mx regimens
-watch for renal impairment and potential CNS toxicity- esp 40-100 mg/m2/d or total 200 mg/m2 with accumulation (happens ~2 months later)
-immunosuppressive (like cyclophos) so it’s good for NMA regimens
Ibrutinib (imbruvica)
BTK inhibitor
-CLL
-used to tx steroid refractory chronic GVHD (less evidence than ruxolitinib and belumosudil)
-DDI with azoles that are dose adjusted specifically based on indication
ADRs: cardiac toxicity (afib, HTN), bleeding (hold for surgery), arthralgia/myalgia, transient lymphocytosis)
cGVHD: skin, oral, GI
Letermovir (Prevymis)
Antiviral
-prevents clinically significant CMV in allogenic recipients who are CMV positive (R+)
-Started after HCT and continued through day 100
-dose adjust if given with cyclosporin
Maribavir (Livtencity)
Antiviral
-post transplant refractory CMV infection- refractory to IV ganciclovir
-given for 8 weeks
Melphalan (Alkeran, Evomela)
Alkylating agent
-most commonly used in autologous regimens for myeloma
-short stability
-given with cryotherapy (ice chips chewed) to prevent mucositis
-VOD
-renal elimination
Methotrexate
Antimetabolite
-used to prevent GVHD
-typically 4 doses beginning day +1 in mini-doses (can omit 4th dose if hemorrhagic mucositis)
-no dose adjustment for DDI and no leucovorin since mini-doses
-mucositis
-delayed engraftment
Decrease by 50% for scr >2x BL, LFT>200, or bili >5
Motixaforide (Aphexda)
CXCR4 antagonist
-autologous stem cell mobilization in combo with G-CSF
Premedicate with H1 and H2 and leukotriene receptor blocker to prevent hypersensitivity rxn
Mycophenolate mofetil (Cellcept)
Immunosuppressant
-used instead of MTX in reduced intensity or non-myeloablative regimens to prevent GVHD
-less commonly used drug for GVHD prevention by depleting T-cells
Omidubicel-onlv (Omisirge)
Nicotinamide-modified allogeneic hematopoietic progenitor cell therapy
-used for expansion of umbilical cord blood cells leading to decreased time to neutrophil and plt recovery
Ruxolitinib (Jakafi)
JAK inhibitor
-used to tx steroid refractory GVHD
-dose adjust for crcl, plt, and bilirubin
-no adjustment needed for posaconazole, voriconazole, or fluconazole for the GVHD indication
ADR: myelosuppression, infxns (CMV), edema, LFTs, hemorrhage, HLD, high triglycerides
cGVHD: skin, oral, GI, liver, lung, MSK
Sirolimus (Rapamune)
mTOR inhibitor
-used to prevent GVHD
-can be used as immunosuppressant when pts develop TMA/MAHA with calcineurin inhibitors
-long t1/2 so monitor trough once weekly
-3A4 substrate- Dec from azoles
-DI with statins- rhabdo
-Increased risk of VOD
-thrombotic microangiopathy
-3-14 ng/mL
Tacrolimus (Prograf)
Calcineurin inhibitor
-used to prevent and tx GVHD
-renal toxicity, hypomagnesemia, hyperkalemia, and HTN
-requires TDM
-rarely causes PRES (posterior reversible encephalopathic syndrome)
-many DDIs as it is a 3A4 substrate
-5-15 ng/mL (5-10 if given with sirolimus)
-IV:PO 1:3-4
Thiotepa (Tepadina)
Alkylator
-used in CNS penetration in auto and allo conditioning regimens (good if leptomeningeal or parenchyma involvement)
-hyperpigmentation-excreted in sweat- BID skin cleansing during and x48h after therapy. Change linens
-DLTs: mucositis, neurotoxicity
-give after cyclophosphamide (prevents activation of cyclophosphamide
Indications for autologous HCT
-multiple myeloma
-Hodgkin’s lymphoma
-DLBCL
-systemic sclerosis
Indications for allogenic HCT
-multiple myeloma-not preferred
-Hodgkin’s lymphoma-not preferred
-DLBCL-no preferred
-AML
-MDS
-ALL
-CML, CLL
-severe aplastic anemia
-SSD
Mobilization methods autologous and allogeneic
Autologous:
-single agent G-CSF
-chemo (cyclophos or etoposide) + G-CSF
-plerixafor + G-CSF
Allogeneic:
-single agent G-CSF only
Myeloma mobilization
Single agent G-CSF 10-16 mcg/kg/d if all of the following
-no more than 1 prior line of chemo
-no prior Melphalan
-no more than 4 cycles lenolidamide and wait 2-4 weeks after last dose
-Use plerixafor if low CD34+ (<10)
-if prior lenalidomide:
-collect after no more than 2-4 cycles
-can use G-CSF + chemo + plerixafor
NHL mobilization
-single agent G-CSF has high failure rate
-plerixafor if low CD34+(<10)
-chemo based mobilization can be incorporated into planned salvage chemo
Which type of conditioning regimen is always used for autologous HCT?
Myeloablative
-allogeneic can use all three types depending on the situation- myeloablative is better for young/fit pts
Who gets myeloablative conditioning ?
-AML, MDS, ALL, CML
-young, low comorbidities
TBI based in ALL
Who gets reduced intensity or no myeloablative conditioning?
-older, significant comorbidities
-prior HCT
-CLL, NHL, HL, plasma cell disorders
Palifermin
Mucositis prevention for autologous HCT receiving HD-chemo + TBI
TBI antiemetics
High risk RT for Emesis
5HT3 + dex on day of and 1 day after
Sinusoidal obstruction syndrome prevention
Ursodiol 12 mg/kg/day through days 1-30 (or 1-90)
Risk fx: allogeneic, myeloablative, busulfan, ozogamicin, pre-existing liver injury, iron overload
Avoid hepatotoxins, APAP, azoles, progestins, estrogens
Sinusoidal obstruction syndrome treatment
Defibrotide 6.25 mg/kg iv Q6h x 21d (max of 60 days)
Most commonly occurs in first 3 weeks
GVHD prevention: myeloablative MRD or MUD
CNI + MTX +/- ATG
Consider cyclosporine for related and tacrolimus for unrelated donor